TABLE OF CONTENTS
1 INTRODUCTION 54
1.1 OBJECTIVES OF THE STUDY 54
1.2 MARKET DEFINITION 54
1.3 OVERVIEW OF GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET 54
1.4 LIMITATIONS 56
1.5 MARKETS COVERED 57
2 MARKET SEGMENTATION 60
2.1 MARKETS COVERED 60
2.2 GEOGRAPHICAL SCOPE 61
2.3 YEARS CONSIDERED FOR THE STUDY 62
2.4 CURRENCY AND PRICING 62
2.5 DBMR TRIPOD DATA VALIDATION MODEL 63
2.6 MULTIVARIATE MODELLING 66
2.7 PRODUCT TYPE LIFELINE CURVE 66
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 67
2.9 DBMR MARKET POSITION GRID 68
2.10 MARKET END USER COVERAGE GRID 70
2.11 VENDOR SHARE ANALYSIS 71
2.12 SECONDARY SOURCES 72
2.13 ASSUMPTIONS 72
3 EXECUTIVE SUMMARY 73
4 PREMIUM INSIGHTS 76
4.1 PESTEL ANALYSIS 79
4.2 PORTER'S 5 FORCES 80
5 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, REGULATIONS 81
5.1 REGULATORY SCENARIO IN THE U.S. 81
5.2 REGULATORY SCENARIO IN AUSTRALIA 82
5.3 REGULATORY SCENARIO IN JAPAN 82
5.4 REGULATORY SCENARIO IN CHINA 82
6 MARKET OVERVIEW 84
6.1 DRIVERS 86
6.1.1 GROWING PREVALENCE OF LEUKEMIA CANCER 86
6.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN LEUKEMIA DIAGNOSTICS 88
6.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 88
6.1.4 INCREASE IN AWARENESS REGARDING LEUKEMIA CANCER 89
6.2 RESTRAINTS 90
6.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF LEUKEMIA DIAGNOSTIC PRODUCTS 90
6.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF LEUKEMIA 90
6.3 OPPORTUNITIES 91
6.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR LEUKEMIA 91
6.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 91
6.3.3 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 92
6.4 CHALLENGES 93
6.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 93
6.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 93
7 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE 94
7.1 OVERVIEW 95
7.2 INSTRUMENTS 98
7.2.1 BIOPSY INSTRUMENTS 99
7.2.1.1 BONE MARROW BIOPSY 99
7.2.1.2 NEEDLE BIOPSY 99
7.2.1.3 SURGICAL BIOPSY 99
7.2.1.4 OTHERS 100
7.2.2 PATHOLOGY-BASED INSTRUMENTS 100
7.2.2.1 PCR INSTRUMENTS 100
7.2.2.2 SLIDE STAINING SYSTEMS 100
7.2.2.3 TISSUE PROCESSING SYSTEMS 100
7.2.2.4 CELL PROCESSORS 100
7.2.2.5 OTHER PATHOLOGY-BASED INSTRUMENTS 101
7.2.3 IMAGING INSTRUMENTS 101
7.2.3.1 ULTRASOUND SYSTEMS 101
7.2.3.2 CT SYSTEMS 101
7.2.3.3 MRI SYSTEMS 101
7.2.3.4 OTHERS 101
7.2.4 OTHERS 102
7.3 CONSUMABLES & ACCESSORIES 102
7.3.1 KITS 103
7.3.1.1 PCR KITS 103
7.3.1.2 DNA POLYMERASE KITS 103
7.3.1.3 NUCLEIC ACID ISOLATION KITS 103
7.3.1.4 OTHERS 104
7.3.2 REAGENTS 104
7.3.2.1 ASSAYS 104
7.3.2.2 BUFFERS 104
7.3.2.3 PRIMERS 104
7.3.2.4 OTHERS 104
7.3.3 PROBES 105
7.3.4 OTHER CONSUMABLES 105
8 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE 106
8.1 OVERVIEW 107
8.2 BLOOD TEST 110
8.2.1 COMPLETE BLOOD COUNT (CBC) 111
8.2.2 BLOOD CHEMISTRY TESTS 111
8.2.3 OTHERS 111
8.3 IMAGING TEST 111
8.3.1 COMPUTED TOMOGRAPHY (CT) SCAN 112
8.3.2 MRI 112
8.3.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 113
8.3.4 OTHERS 113
8.4 BONE MARROW TESTS 113
8.4.1 BONE MARROW ASPIRATE 114
8.4.2 BONE MARROW BIOPSY 114
8.4.3 OTHERS 114
8.5 GENETIC TESTS 114
8.5.1 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 115
8.5.2 KARYOTYPING 115
8.5.3 OTHERS 115
8.6 BIOMARKER TEST 115
8.6.1 GENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 116
8.6.2 EPIGENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 117
8.6.3 PROTEOMIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 117
8.7 IMMUNOPHENOTYPING 117
8.7.1 FLOW CYTOMETRY 118
8.7.2 IMMUNOHISTOCHEMISTRY 118
8.7.3 OTHERS 118
8.8 OTHERS 118
9 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE 120
9.1 OVERVIEW 121
9.2 MYELOBLASTIC (M0) 124
9.3 MYELOBLASTIC (M1) 124
9.4 MYELOBLASTIC (M2) 125
9.5 PROMYELOCYTIC (M3) 126
9.6 MYELOMONOCYTIC (M4) 127
9.7 MONOCYTIC (M5) 127
9.8 ERYTHROLEUKEMIA (M6) 128
9.9 MEGAKARYOCYTIC (M7) 129
10 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP 130
10.1 OVERVIEW 131
10.2 65 AND ABOVE 134
10.3 30-65 134
10.4 BELOW 21 135
10.5 21-29 136
11 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER 138
11.1 OVERVIEW 139
11.2 MALE 142
11.3 FEMALE 142
12 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER 144
12.1 OVERVIEW 145
12.2 HOSPITALS 148
12.3 ASSOCIATED LABS 148
12.4 INDEPENDENT DIAGNOSTIC LABORATORIES 149
12.5 DIAGNOSTIC IMAGING CENTERS 150
12.6 CANCER RESEARCH INSTITUTES 150
12.7 OTHERS 151
13 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 153
13.1 OVERVIEW 154
13.2 DIRECT TENDER 157
13.3 RETAIL SALES 157
14 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION 159
14.1 OVERVIEW 160
14.2 NORTH AMERICA 166
14.2.1 U.S. 177
14.2.2 CANADA 183
14.2.3 MEXICO 189
14.3 EUROPE 195
14.3.1 GERMANY 207
14.3.2 UNITED KINGDOM 213
14.3.3 FRANCE 219
14.3.4 ITALY 225
14.3.5 SPAIN 231
14.3.6 RUSSIA 237
14.3.7 NETHERLANDS 243
14.3.8 SWITZERLAND 249
14.3.9 BELGIUM 255
14.3.10 TURKEY 261
14.3.11 REST OF EUROPE 267
14.4 ASIA-PACIFIC 268
14.4.1 CHINA 280
14.4.2 JAPAN 286
14.4.3 INDIA 292
14.4.4 AUSTRALIA 298
14.4.5 SOUTH KOREA 304
14.4.6 INDONESIA 310
14.4.7 PHILIPPINES 316
14.4.8 THAILAND 322
14.4.9 MALAYSIA 328
14.4.10 VIETNAM 334
14.4.11 SINGAPORE 340
14.4.12 REST OF ASIA-PACIFIC 346
14.5 SOUTH AMERICA 347
14.5.1 BRAZIL 358
14.5.2 ARGENTINA 364
14.5.3 REST OF SOUTH AMERICA 370
14.6 MIDDLE EAST AND AFRICA 371
14.6.1 SOUTH AFRICA 383
14.6.2 SAUDI ARABIA 389
14.6.3 UAE 395
14.6.4 EGYPT 401
14.6.5 ISRAEL 407
14.6.6 REST OF MIDDLE EAST AND AFRICA 413
15 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY LANDSCAPE 414
15.1 COMPANY SHARE ANALYSIS: GLOBAL 414
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 415
15.3 COMPANY SHARE ANALYSIS: EUROPE 416
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 417
16 SWOT ANALYSIS 418
17 COMPANY PROFILE 419
17.1 CANON MEDICAL SYSTEMS CORPORATION. 419
17.1.1 COMPANY SNAPSHOT 419
17.1.2 REVENUE ANALYSIS 419
17.1.3 COMPANY SHARE ANALYSIS 420
17.1.4 PRODUCT PORTFOLIO 420
17.1.5 RECENT DEVELOPMENT 420
17.2 SYSMEX CORPORATION 421
17.2.1 COMPANY SNAPSHOT 421
17.2.2 REVENUE ANALYSIS 421
17.2.3 COMPANY SHARE ANALYSIS 422
17.2.4 PRODUCT PORTFOLIO 422
17.2.5 RECENT DEVELOPMENT 422
17.3 EPIGENOMICS AG. 423
17.3.1 COMPANY SNAPSHOT 423
17.3.2 REVENUE ANALYSIS 423
17.3.3 COMPANY SHARE ANALYSIS 424
17.3.4 PRODUCT PORTFOLIO 424
17.3.5 RECENT DEVELOPMENT 424
17.4 MYRIAD GENETICS, INC.. 425
17.4.1 COMPANY SNAPSHOT 425
17.4.2 REVENUE ANALYSIS 425
17.4.3 COMPANY SHARE ANALYSIS 426
17.4.4 PRODUCT PORTFOLIO 426
17.4.5 RECENT DEVELOPMENT 426
17.5 F. HOFFMANN- LA ROCHE LTD 427
17.5.1 COMPANY SNAPSHOT 427
17.5.2 REVENUE ANALYSIS 427
17.5.3 COMPANY SHARE ANALYSIS 428
17.5.4 PRODUCT PORTFOLIO 428
17.5.5 RECENT DEVELOPMENT 428
17.6 ABBOTT 429
17.6.1 COMPANY SNAPSHOT 429
17.6.2 REVENUE ANALYSIS 429
17.6.3 PRODUCT PORTFOLIO 430
17.6.4 RECENT DEVELOPMENT 430
17.7 AGILENT TECHNOLOGIES, INC. 431
17.7.1 COMPANY SNAPSHOT 431
17.7.2 REVENUE ANALYSIS 431
17.7.3 PRODUCT PORTFOLIO 432
17.7.4 RECENT DEVELOPMENT 432
17.8 BD 433
17.8.1 COMPANY SNAPSHOT 433
17.8.2 REVENUE ANALYSIS 433
17.8.3 PRODUCT PORTFOLIO 434
17.8.4 RECENT DEVELOPMENT 434
17.9 BIOMERIEUX 435
17.9.1 COMPANY SNAPSHOT 435
17.9.2 PRODUCT PORTFOLIO 435
17.9.3 RECENT DEVELOPMENT 435
17.10 BIO-RAD LABORATORIES, INC. 436
17.10.1 COMPANY SNAPSHOT 436
17.10.2 REVENUE ANALYSIS 436
17.10.3 PRODUCT PORTFOLIO 437
17.10.4 RECENT DEVELOPMENT 437
17.11 DIASORIN S.P.A. 438
17.11.1 COMPANY SNAPSHOT 438
17.11.2 REVENUE ANALYSIS 438
17.11.3 PRODUCT PORTFOLIO 439
17.11.4 RECENT DEVELOPMENTS 439
17.12 EXACT SCIENCES CORPORATION 440
17.12.1 COMPANY SNAPSHOT 440
17.12.2 REVENUE ANALYSIS 440
17.12.3 PRODUCT PORTFOLIO 441
17.12.4 RECENT DEVELOPMENTS 441

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.